W
WAVEMAN · COMPANY
TAK · Takeda Pharmaceutical Co Ltd
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

TAK

TAKEDA PHARMACEUTICAL CO LTD
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001395064
FORM 144 · 18☆ WATCH
INSIDER NET · 180D
-$12.4M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
213
13F, latest reported quarter
REVENUE GROWTH
-
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$12.4M over 180 days
-$12.4M over 90 days
below 86% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
213 funds added or opened last quarter
more than 88% of Pharma & Biotech
REVENUE
no revenue reported in any filing
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$12.4M across 13 people in 180 days.
213 funds added or opened positions in the latest 13F quarter, of 382 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +21.7%
+21.7%12M
-13%-0%+12%+24%2025-092025-102025-122026-032026-052026-072026-09 2026-08-10 · Plump Andrew Stewart sold $2.8M2026-09-02 · Plump Andrew Stewart sold $2.1M2026-08-10 · Kim Julie So-Young sold $1.5M2026-08-10 · Bitetti Teresa Marie sold $855.2K2026-08-10 · Duprey Lauren Rusckowski sold $813.7K2026-08-10 · Greenway Nicola Deidre Petal sold $588.7K2026-08-10 · Platford Giles Richard sold $531.5K2026-08-10 · Furney Natalie Anne Marie sold $527.8K2026-08-10 · Ricci Gabriele sold $429.0K2026-08-10 · Pignagnoli Agosti Marcello sold $392.6K2026-08-19 · Plump Andrew Stewart sold $363.3K2026-08-11 · Shannon Elaine Mary sold $357.4K2026-08-10 · Pacheco Rhonda Janice sold $289.0K2026-08-10 · Farajallah Awny Samaan Botros sold $239.5K2026-08-18 · Greenway Nicola Deidre Petal sold $235.1K2026-08-10 · Ibrahim Ramy Riad Ahmed sold $124.4K2026-08-10 · Greenway Nicola Deidre Petal sold $115.8K2026-08-10 · Shannon Elaine Mary sold $68.0K2026-08-10 · Greenway Nicola Deidre Petal sold $17.1K2026-09-02 · Plump Andrew Stewart filed to sell $2.1M2026-08-19 · Plump Andrew Stewart filed to sell $363.3K2026-08-14 · Nicola Greenway filed to sell $225.7K2026-08-10 · Elaine Shannon filed to sell $355.3K2026-08-06 · Nicola Greenway filed to sell $578.6K2026-07-13 · Teresa Bitetti filed to sell $908.0K2026-07-13 · Lauren Rusckowski Duprey filed to sell $863.9K2026-07-13 · Awny Farajallah filed to sell $254.4K2026-07-13 · Natalie Furney filed to sell $560.4K2026-07-13 · Nicola Greenway filed to sell $123.1K2026-07-13 · Ramy Riad filed to sell $132.1K2026-07-13 · Julie Kim filed to sell $1.6M2026-07-13 · Rhonda Pacheco filed to sell $306.8K2026-07-13 · Marcello Pignagnoli Agosti filed to sell $416.9K2026-07-13 · Giles Platford filed to sell $564.4K2026-07-13 · Andrew Plump filed to sell $3.0M2026-07-13 · Gabriele Ricci filed to sell $455.5K2026-07-13 · Elaine Shannon filed to sell $72.4K
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $12.4M sold by insiders over 180 days, 213 funds added last quarter, $12.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, TAKEDA PHARMACEUTICAL CO LTD insiders sold a net $12.4M of stock across 19 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
Plump Andrew Stewart
President, R&D
SELL
2026-09-02
116,191.0
$2.1M
Plump Andrew Stewart
President, R&D
SELL
2026-08-19
19,651.0
$363.3K
Greenway Nicola Deidre Petal
Chief Human Resources Officer
SELL
2026-08-18
12,980.0
$235.1K
Shannon Elaine Mary
Pres., Global Supply & Quality
SELL
2026-08-11
20,363.0
$357.4K
Greenway Nicola Deidre Petal
Chief Human Resources Officer
SELL
2026-08-10
975.0
$17.1K
19 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 14 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Capital Research Global Investors
19,297,680.0 sh
$309.3M
FMR LLC
9,599,302.0 sh
$153.9M
MORGAN STANLEY
6,994,924.0 sh
$112.1M
ADAGE CAPITAL PARTNERS GP, L.L.C.
6,050,771.0 sh
$97.0M
GOLDMAN SACHS GROUP INC
5,125,032.0 sh
$82.2M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Plump Andrew Stewart
FILED 2026-09-02
$2.1M
Plump Andrew Stewart
FILED 2026-08-19
$363.3K
Nicola Greenway
FILED 2026-08-14
$225.7K
Elaine Shannon
FILED 2026-08-10
$355.3K
Nicola Greenway
FILED 2026-08-06
$578.6K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Steward Values Enhanced International Fund
$11.9M POSITION · AS OF 2026-04-30
3.9%
Catalyst/MAP Global Equity Fund
$3.1M POSITION · AS OF 2026-03-31
3.5%
VanEck Pharmaceutical ETF
$40.5M POSITION · AS OF 2026-03-31
3.1%
Catalyst/MAP Global Balanced Fund
$426.0K POSITION · AS OF 2026-03-31
2.9%
Amplify CWP International Enhanced Dividend Income ETF
$16.4M POSITION · AS OF 2026-03-31
1.6%
SGI Global Equity Fund
$1.3M POSITION · AS OF 2026-02-28
1.6%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-032024-032023-032022-03
NET INCOME$108.1B$144.2B$317.0B$230.2B
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →